Enhancing risk stratification in early colon cancer with TNM-I (Immune) staging: focus on stage II T4N0 patients

DATE:  July 07, 2020

TIME:   9:00 am PDT

The widely used TNM staging system is poorly predictive of response to adjuvant chemotherapy in Stage II and III colon cancer. As a result, there is overutilization of adjuvant chemotherapy in some patients at low risk for recurrence, and underutilization in patients at high risk for recurrence. There is a strong unmet need for a better prognostic and predictive tool to personalize treatment decisions in colorectal cancer.

The World Health Organization (WHO) recently introduced immune response as an essential and desirable diagnostic criterion for CRC alongside standard histological parameters, indicating that assessment of immune response is now an essential complement to standard staging procedures. Immunoscore® is the first consensus, standardized and commercially available test clinically validated for this assessment.

This webinar will focus on our latest data presented at ASCO 2020 and ESMO-GI 2020. First, prognostic performance on T4N0 colon cancer patients will be presented, showing that Immunoscore® identifies which patients have a lower risk of recurrence who might be spared adjuvant chemotherapy. Secondly, use of TNM-Immune (TNM-I) classification system to determine treatment benefit in selected patients will be discussed.

Learning Objectives:

• Understand the value of Immunoscore® on top of standard tools for early stage Colon Cancer patients
• Evaluate impact of Immunoscore® on treatment decisions for T4N0 Colon Cancer patients
• Outline the utility of a TNM-I approach for Colon Cancer risk assessment

Webinars will be available for unlimited on-demand viewing after live event.

LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.